The Online Investor
Hepion Pharmaceuticals Inc (HEPA)

Hepion Pharmaceuticals is a biopharmaceutical company focused on the development of pleiotropic drug therapy for treatment of chronic liver disease. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Co.'s cyclophilin inhibitor, CRV431, is being developed to address these pathologies. CRV431 is a cyclophilin inhibitor that targets multiple biochemical pathways involved in the progression of liver disease. CRV431 additionally shows antiviral activity towards hepatitis B, C, and D viruses which also trigger liver disease.
Company Name: 
Hepion Pharmaceuticals Inc
Drugs & Pharmaceuticals
Number of ETFs Holding HEPA: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 
Quotes delayed 20 minutes

Strong Buy (4.00 out of 4)
91st percentile
(ranked higher than approx. 91% of all stocks covered)

Analysts' Target Price:
HEPA Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Hepion Pharmaceuticals Inc (HEPA) Page | The Online Investor Page |

Copyright © 1998 - 2021, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.